Category Archives: Commentary

Slippery slopes and slippery flats

In this episode of my decade-long quest to correct popular British misconceptions, I wish to turn to one of my most geeky obsessions: trains. In particular, I would like to address a particularly British obsession, which many take as a signal of the lapse of British know-how from its mid-Empire industrial-revolution heights.

This is, of course, ‘leaves on the line‘. Why – demand the British public – must timetables run five to ten minutes slower when there are more leaves on the ground? Why do no other modern countries suffer from these ills? And why does the railway take no action over this commuting scourge?

Continue reading →

IWD 2021 and the Gender Pay Gap

Throughout the pandemic, the statistics on division of childcare and home-schooling responsibilities have been shocking: mothers are taking on 150% more homeschooling than fathers (1), while 71% of working mothers’ furlough applications were rejected (2).  A third of working mothers reported having lost  some or all work due to a lack of childcare during the pandemic, with this figure rising to 44% for  BAME mothers. On top of this, 90% of the UK’s 2 million single parents are women (3). These unequal divisions are threatening to undo decades of progress towards gender equality.

In April 2019, the pay gap between men and women in the UK was 17.3% (4), and at the current rate of gender pay gap reduction, the gap will not be closed until 2052 (5).  The causes of this gap continue to be unequal caring responsibilities,  more women in low-paid work and (illegal) discrimination. BAME women are also subject to the ethnicity pay gap.  While this varies regionally and by ethnicity, in London in 2018 the overall figure was 23% (6).

Continue reading →

Commercialising your research: Where to start?

If you look at some of the biggest technology companies in the world, from Google and Facebook to hardware companies like Dell or even biotech unicorns like Oxford’s own Oxford Nanopore, all of them started on university campuses. If you are a researcher interested in finding out how to make the first steps to commercialise your research here is a quick guide:

Continue reading →

The Coronavirus Antibody Database: 10 months on, 10x the data!

Back in May 2020, we released the Coronavirus Antibody Database (‘CoV-AbDab’) to capture molecular information on existing coronavirus-binding antibodies, and to track what we anticipated would be a boon of data on antibodies able to bind SARS-CoV-2. At the time, we had found around 300 relevant antibody sequences and a handful of solved crystal structures, most of which were characterised shortly after the SARS-CoV epidemic of 2003. We had no idea just how many SARS-CoV-2 binding antibody sequences would come to be released into the public domain…

10 months later (2nd March 2021), we now have tracked 2,673 coronavirus-binding antibodies, ~95% with full Fv sequence information and ~5% with solved structures. These datapoints originate from 100s of independent studies reported in either the academic literature or patent filings.

The entire contents CoV-AbDab database as of 2nd March 2021.
Continue reading →

A new Graduate students (unexperienced) guide to academic literature.

Given this is my first ever attempt at a blog post, let alone one on such a highly regarded platform I feel it’s proper that I introduce myself. Hi, my name is Maranga, I am a second-year SABS student starting my DPhil project in Small molecules, and honestly, I really don’t like reading. Especially, scientific journals. Now I can appreciate this does not bode well given my chosen career path, however, my aversion for reading is not new (shoutout to Biff, Chip and Kipper) and hopefully not permanent.

Continue reading →

How COVID-19 affected my (undergrad) masters

The COVID-19 pandemic hit us all in different ways, and this is a short look into how it affected me, a biochemistry undergrad doing my masters project in OPIG.

The first thing that impacted me was the move to working from home. Now you might think that as the group does only computational work that our work might not be too affected by working from home, as all the servers etc. can be accessed remotely. To a certain extent, this is true, it is possible to work from home for starters. Things may well be right as rain for a few people, but it wasn’t for me. I think a lot of people are finding that things take longer when not in the office even under the best circumstances. Technology and equipment can also reduce your productivity quite majorly. Not having a very fast computer (mine is 5 years old and you can tell) or poor chairs that give you backache (living that wooden dining room chair life) are just examples of things that affect your productivity, and also not something most of can do about.

Continue reading →

10 reasons why LGBT Pride is still necessary

We are starting the LGBT Pride Month, which commemorates the Stonewall Riots (1959). It has rained a lot since that June 51 years ago when a group of transgender, gay, lesbian, and bisexual people rebelled against the police fighting for their rights, inexistent at that time. Fortunately, the situation has changed for the better: in 2011 the UN National Assembly approved the first Human rights, sexual orientation and gender identity resolution, and the difference between sex and gender is not and up to date, 29 different countries recognise same-sex marriage. Therefore, do we still need to celebrate/commemorate/revindicate LGBT Pride? Yes, yes and one thousand times yes. Why? Here I give you only 10 reasons, but it would not be difficult finding 100 more.

Continue reading →

Converting Miles to Kilometres – An inefficient but neat method

Picture this: You’re a zealous acolyte of the metric system, with a rare affliction that makes multiplying decimal numbers impossible. You’re on holiday in the UK, where road signs give distances in miles. Heathens! How can you efficiently estimate the number of kilometres without multiplying by approximately 1.60934?

Continue reading →

State of the art in AI for drug discovery: more wet-lab please

The reception of ML approaches for the drug discovery pipeline, especially when focused on the hit to lead optimization process, has been rather skeptical by the medchem community. One of the main drivers for that is the way many ML publications benchmark their models: Historic datasets are split into two parts, with the larger part used to train and the smaller to test ML models. In order to standardize that validation process, computational chemists have constructed widely used benchmark datasets such as the DUD-E set, which is commonly used as a standard for protein-ligand binding classification tasks. Common criticism from medicinal chemists centers on the main problem associated with benchmark datasets: the absence of direct lab validation.

Continue reading →